Use of Dopamine Agonists in Cardiovascular Medicine
Intravenous DA infusion is perhaps the major pharmacological intervention in use in the management of cardiovascular disorders in Intensive Care Units. For this therapeutic advance, clinicians owe a debt of gratitude to Goldberg and his colleagues (McDonald et al., 1964; Goldberg, 1972, 1974). Yet the cardiovascular actions of DA are complex and dose-related. The effects of DA reflect the sum of many distinct and even directionally opposite cardiovascular responses to the actions of DA on a variety of different catecholamine receptors (Goldberg, 1972; Goldberg et al., 1978; Goldberg and Kohli 1979, 1983).
Unable to display preview. Download preview PDF.
- Baumann, G., Permanetter, B., Pfafferot, C. and Busch, U. (1986). Acute haemo-dynamic effects of dopexamine, a new positive inotropic and vasodilator substance, compared with dobutamine and sodium nitroprusside in patients with chronic myocardial insufficiency. Z. Kardiol., 75 (51), 71Google Scholar
- Dawson, J. R., Thompson, D. S., Signy, M., Juul, S. M., Turnbull, P., Jenkins, B. S. and Webb-Peploe, M. M. (1985). Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br. Heart J., 54, 313–320PubMedPubMedCentralCrossRefGoogle Scholar
- Goldberg, L. I. (1972). Cardiovascular and renal actions of dopamine. Potential clinical applications. Pharmac. Rev., 24, 1–24Google Scholar
- Goldberg, L. I. and Kohli, J. D. (1979). Peripheral pre- and post-synaptic dopamine receptors: Are they different from dopamine receptors in the central nervous system? Commun. Psychopharmac., 3, 447–456Google Scholar
- Hahn, R. A. and McDonald, B. R. (1984). Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist. J. Pharmac. Exp. Ther., 230, 538–568Google Scholar
- Hahn, R. A., Wardell, J. R., Sarau, H. M. and Ridley, P. T. (1982). Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther., 223, 305–314Google Scholar
- McGrath, B. P., Jover, B. F., Trigg, L. and Arnolda, L. F. (1987). Adriamycin-induced cardiomyopathic heart failure in the rabbit. In Kawai, C. and Abelmann, W. (Eds.), Pathogenesis of Myocarditis and Cardiomyopathy. Recent experimental and clinical studies, University of Tokyo Press, Tokyo, pp. 121–133Google Scholar
- Merrill, A. J. (1945). Edema and decreased renal blood flow in patients with chronic congestive heart failure: Evidence of ‘forward failure’ as the primary cause of edema. J. Clin. Invest., 49, 389–400Google Scholar
- Rajfer, S. I. and Goldberg, L. I. (1983). Dopamine in the treatment of heart failure. Eur. Heart J., 3, 103–106Google Scholar